BSE: 539787 | NSE: HCG | Hospital & Healthcare Services | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Healthcare Global Enterprises Ltd is a average quality company.
The key valuation ratios of Healthcare Global Enterprises Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Healthcare Global Enterprises Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 4.4% | 4% | 6.1% | 7.7% | 6.1% | 1.6% | -12.6% | 10.5% | 8% | 7.2% | - |
| Value Creation Index ⓘ | -0.7 | -0.7 | -0.6 | -0.5 | -0.6 | -0.9 | -1.9 | -0.3 | -0.4 | -0.5 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 420 | 471 | 545 | 586 | 641 | 688 | 609 | 850 | 1,006 | 1,099 | 1,146 |
| Sales YoY Gr. | - | 12.1% | 15.7% | 7.6% | 9.3% | 7.5% | -11.6% | 39.6% | 18.3% | 9.3% | - |
| Adj EPS ⓘ | 0.1 | -0.2 | 2.3 | 2 | 0.8 | -6.1 | -15.3 | -3.7 | 2.9 | 2.4 | 2.5 |
| YoY Gr. | - | -520% | NA | -11.1% | -61% | -883.3% | NA | NA | NA | -18.4% | - |
| BVPS (₹) ⓘ | 38.2 | 61 | 63.5 | 69.6 | 72.7 | 68.5 | 69.7 | 78.5 | 81.5 | 84.1 | 87.6 |
| Adj Net Profit ⓘ | 0.4 | -1.8 | 19.3 | 17.4 | 6.9 | -54.2 | -192 | -51.3 | 40.7 | 33.3 | 34 |
| Cash Flow from Ops. ⓘ | 50.5 | 57.8 | 53.9 | 66.4 | 87 | 86.3 | 70.9 | 124 | 130 | 195 | - |
| Debt/CF from Ops. ⓘ | 6.2 | 3.4 | 4 | 4 | 4.9 | 5.7 | 3.4 | 0.9 | 0.9 | 2 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 11.3% | 11.4% | 21.8% | 9.3% | ||||
| Adj EPS ⓘ | 53.7% | 25.1% | NA | -18.4% | ||||
| BVPSⓘ | 9.2% | 3% | 6.5% | 3.2% | ||||
| Share Price | - | 33.2% | 22.9% | 26.8% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0.1 | -0.5 | 3.6 | 2.9 | 1.1 | -8.6 | -24.9 | -5.1 | 3.6 | 2.9 | 2.9 |
| Op. Profit Mgn % ⓘ | 13.5 | 13.6 | 15.2 | 14 | 14.7 | 16.8 | 12.1 | 17.3 | 16.9 | 17.9 | 18.3 |
| Net Profit Mgn % ⓘ | 0.1 | -0.4 | 3.5 | 3 | 1.1 | -7.9 | -31.5 | -6 | 4.1 | 3 | 3 |
| Debt to Equity ⓘ | 1.2 | 0.4 | 0.4 | 0.4 | 0.7 | 0.8 | 0.3 | 0.1 | 0.1 | 0.3 | 0.2 |
| Working Cap Days ⓘ | 129 | 128 | 130 | 161 | 211 | 240 | 257 | 150 | 124 | 141 | 83 |
| Cash Conv. Cycle ⓘ | -9 | -18 | -16 | -3 | 10 | 22 | 38 | 26 | 26 | 23 | 21 |
Return on Equity has increased versus last 3 years average to 2.90%
Sales growth is growing at healthy rate in last 3 years 21.77%
Net Profit has been subdued in last 3 years 0.00%
Sales growth is not so good in last 4 quarters at 7.61%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 2.5 | 4.1 |
| TTM Sales (₹ Cr.) | 1,146 | 2,042 |
| BVPS (₹.) ⓘ | 87.6 | 61.8 |
| Reserves (₹ Cr.) ⓘ | 1,082 | 722 |
| P/BV ⓘ | 5.35 | 7.58 |
| PE ⓘ | 190.40 | 114.58 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 310.10 / 506.60 |
| All Time Low / High (₹) | 62.95 / 506.60 |
| Market Cap (₹ Cr.) | 6,534 |
| Equity (₹ Cr.) | 139.4 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 40.2 |
| Pledged * | 3.00 | 3.09 | 3.09 | 3.09 | 3.09 | 3.09 | 0.00 | 3.09 | 3.09 | 3.09 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 420 | 471 | 545 | 586 | 640 | 688 | 609 | 850 | 1,006 | 1,099 |
| Operating Expenses ⓘ | 364 | 407 | 462 | 504 | 546 | 573 | 535 | 703 | 837 | 903 |
| Manufacturing Costs | 120 | 141 | 158 | 159 | 192 | 215 | 196 | 241 | 273 | 296 |
| Material Costs | 131 | 134 | 149 | 155 | 153 | 147 | 138 | 210 | 236 | 246 |
| Employee Cost | 69 | 85 | 98 | 116 | 130 | 143 | 137 | 157 | 175 | 197 |
| Other Costs ⓘ | 43 | 48 | 57 | 75 | 71 | 69 | 65 | 95 | 153 | 164 |
| Operating Profit ⓘ | 56 | 64 | 83 | 82 | 94 | 116 | 73 | 147 | 169 | 196 |
| Operating Profit Margin (%) | 13.4% | 13.5% | 15.2% | 13.9% | 14.7% | 16.8% | 12.1% | 17.3% | 16.8% | 17.9% |
| Other Income ⓘ | 4 | 3 | 7 | 23 | 13 | 12 | 24 | 12 | 22 | 17 |
| Interest ⓘ | 32 | 34 | 16 | 27 | 48 | 83 | 63 | 43 | 41 | 48 |
| Depreciation ⓘ | 33 | 37 | 44 | 44 | 47 | 79 | 87 | 88 | 89 | 94 |
| Exceptional Items ⓘ | -4 | -4 | 0 | 3 | 0 | -31 | -153 | 53 | -3 | -16 |
| Profit Before Tax ⓘ | -8 | -9 | 29 | 37 | 13 | -65 | -205 | 81 | 58 | 55 |
| Tax ⓘ | -5 | -4 | 10 | 12 | 5 | -12 | -14 | 43 | 17 | 21 |
| Profit After Tax | -2 | -5 | 19 | 25 | 7 | -53 | -192 | 38 | 40 | 34 |
| PAT Margin (%) | -0.6% | -1.0% | 3.6% | 4.2% | 1.1% | -7.7% | -31.5% | 4.5% | 4.0% | 3.1% |
| Adjusted EPS (₹) | -0.3 | -0.6 | 2.3 | 2.9 | 0.8 | -6.0 | -15.3 | 2.8 | 2.9 | 2.4 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 267 | 519 | 544 | 605 | 639 | 607 | 873 | 1,091 | 1,133 | 1,171 |
| Share Capital ⓘ | 70 | 85 | 86 | 87 | 88 | 89 | 125 | 139 | 139 | 139 |
| Reserves ⓘ | 197 | 434 | 458 | 518 | 551 | 519 | 748 | 952 | 994 | 1,032 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 277 | 160 | 165 | 219 | 396 | 419 | 214 | 83 | 113 | 362 |
| Long Term Debt | 247 | 123 | 124 | 217 | 346 | 315 | 147 | 82 | 113 | 261 |
| Short Term Debt | 29 | 37 | 41 | 2 | 50 | 104 | 67 | 1 | 0 | 101 |
| Trade Payables | 75 | 97 | 105 | 114 | 106 | 99 | 81 | 96 | 109 | 132 |
| Others Liabilities ⓘ | 70 | 60 | 96 | 165 | 259 | 628 | 379 | 374 | 375 | 523 |
| Total Liabilities ⓘ | 689 | 836 | 910 | 1,103 | 1,400 | 1,754 | 1,547 | 1,644 | 1,730 | 2,188 |
Fixed Assets | ||||||||||
| Gross Block | 566 | 467 | 511 | 591 | 693 | 1,141 | 1,058 | 1,177 | 1,275 | 1,510 |
| Accumulated Depreciation | 162 | 36 | 69 | 99 | 146 | 227 | 313 | 403 | 487 | 572 |
| Net Fixed Assetsⓘ | 405 | 431 | 442 | 492 | 547 | 914 | 745 | 774 | 788 | 938 |
| CWIP ⓘ | 28 | 29 | 33 | 79 | 104 | 44 | 28 | 5 | 9 | 36 |
| Investmentsⓘ | 84 | 155 | 141 | 219 | 299 | 316 | 366 | 439 | 475 | 506 |
| Inventories | 13 | 11 | 15 | 17 | 16 | 13 | 12 | 17 | 21 | 21 |
| Trade Receivables | 64 | 69 | 101 | 126 | 146 | 152 | 147 | 160 | 212 | 204 |
| Cash Equivalents | 13 | 50 | 75 | 15 | 9 | 15 | 14 | 120 | 80 | 237 |
| Others Assetsⓘ | 83 | 91 | 103 | 155 | 280 | 300 | 235 | 129 | 144 | 244 |
| Total Assets ⓘ | 689 | 836 | 910 | 1,103 | 1,400 | 1,754 | 1,547 | 1,644 | 1,730 | 2,188 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 51 | 58 | 54 | 66 | 87 | 86 | 71 | 124 | 130 | 195 |
| PBT ⓘ | -8 | -9 | 29 | 37 | 13 | -65 | -205 | 81 | 58 | 55 |
| Adjustment ⓘ | 64 | 74 | 57 | 60 | 91 | 192 | 285 | 79 | 150 | 168 |
| Changes in Working Capital ⓘ | -5 | -0 | -25 | -32 | 10 | -20 | -49 | -21 | -60 | 5 |
| Tax Paid ⓘ | 0 | -8 | -7 | 1 | -26 | -20 | 40 | -15 | -17 | -33 |
| Cash Flow From Investing Activity ⓘ | -74 | -86 | -73 | -185 | -208 | -116 | -246 | 49 | -138 | -249 |
| Capex | -67 | -90 | -40 | -104 | -123 | -80 | -23 | -42 | -95 | -124 |
| Net Investments | -5 | -3 | 2 | 20 | -15 | 4 | -102 | 189 | -10 | -46 |
| Others ⓘ | -2 | 7 | -35 | -100 | -70 | -40 | -120 | -99 | -32 | -79 |
| Cash Flow From Financing Activityⓘ | 22 | 120 | -14 | 91 | 66 | -3 | 236 | -41 | -42 | 105 |
| Net Proceeds from Shares ⓘ | 10 | 271 | 7 | 35 | 0 | 20 | 453 | 132 | 1 | 2 |
| Net Proceeds from Borrowing ⓘ | 29 | -110 | -9 | 79 | 106 | 36 | -219 | -67 | 14 | 174 |
| Interest Paid ⓘ | -28 | -33 | -12 | -23 | -40 | -66 | -59 | -43 | -36 | -46 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 12 | -8 | 0 | 0 | 0 | 7 | 62 | -63 | -21 | -25 |
| Net Cash Flow ⓘ | -1 | 92 | -33 | -27 | -55 | -32 | 61 | 132 | -49 | 51 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -0.9 | -1.2 | 3.67 | 4.33 | 1.16 | -8.55 | -25.87 | 3.9 | 3.61 | 2.95 |
| ROCE (%) | 4.42 | 3.98 | 6.12 | 7.65 | 6.13 | 1.62 | -12.55 | 10.46 | 8.02 | 7.21 |
| Asset Turnover Ratio | 0.64 | 0.62 | 0.62 | 0.58 | 0.51 | 0.44 | 0.37 | 0.53 | 0.6 | 0.56 |
| PAT to CFO Conversion(x) | N/A | N/A | 2.84 | 2.64 | 12.43 | N/A | N/A | 3.26 | 3.25 | 5.74 | Working Capital Days |
| Receivable Days | 50 | 52 | 57 | 71 | 77 | 79 | 90 | 66 | 68 | 69 |
| Inventory Days | 10 | 9 | 9 | 10 | 10 | 8 | 7 | 6 | 7 | 7 |
| Payable Days | 189 | 235 | 248 | 259 | 263 | 256 | 238 | 154 | 159 | 179 |
Healthcare Global Enterprises was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a private limited company under the Companies Act, 1956. The name of the company was subsequently changed to HealthCare Global Enterprises Private Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on November 14, 2005. The company was converted into a public limited company pursuant to a special resolution passed by its Shareholders at the extraordinary general meeting held on May 20, 2006 and the name of the company was changed to HealthCare Global Enterprises Limited. A fresh certificate of incorporation consequent upon conversion to a public limited company was issued by the RoC on July 5, 2006.
The company is a provider of speciality healthcare services in India focused on cancer and fertility. Under the “HCG” brand, it operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB . Under the “Milann” brand, it operates its fertility centres.
The company’s HCG network operates on a “hub and spoke” model, wherein its HCG centre of excellence in Bengaluru serves as a “hub” to its other cancer centres. Its centre of excellence provides its other centres access to centralised quality control and assurance services; establishes treatment protocols that are adhered to across its HCG network; provides centralised treatment planning and tele-radiology services to help with diagnosis and treatment; conducts weekly central tumour board meetings to review complex cases; and also gives its HCG network access to advanced technologies, such as WBRRS and specialised procedures such as liver transplants and stem cell therapies. This model allows HCG network of cancer centres to leverage the expertise and capabilities of its centre of excellence, which when combined with the diagnostic and treatment facilities at its cancer centres, allows it to deliver quality cancer care to patients across India in a seamless manner.
The company follows a multidisciplinary approach to cancer care across its HCG network, wherein specialist physicians from various disciplines collaborate to provide the best course of treatment for each patient. This allows it to share and develop best practices, build clinical expertise and adopt standardised protocols for diagnosis and treatment, thereby improving the quality of its cancer care services. As a result, the company is able to better serve its patients and ensure consistent clinical outcomes.
Given the large number of patient cases treated across its HCG network, the company is able to efficiently utilise its equipment, technologies and human resources, thereby deriving economies of scale. Furthermore, through the adoption of a centralised drug and consumables formulary, it is able to lower the overall cost of drugs and consumables. Its business model is scalable and when combined with efficient utilisation of resources, it enables it to operate within a competitive cost structure.
Business area of the company
The company is Bangalore based provider of speciality healthcare in India focused on cancer and fertility. It operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed. It also operates fertility centres under the ‘Milann’ brand.
Major events and milestones
Awards and accreditations
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
